Literature DB >> 22850512

Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.

Shahar Rotem1, Erez Bar-Haim, Hila Cohen, Uri Elia, Raphael Ber, Avigdor Shafferman, Ofer Cohen.   

Abstract

This study examines the efficacy, bacterial load, and humoral response of extensively delayed ciprofloxacin or doxycycline treatments following airway exposure of mice to Francisella tularensis subsp. holarctica (strain LVS) or to the highly virulent F. tularensis subsp. tularensis (strain SchuS4). A delay in onset of both antibiotic treatments allowed the rescue of all LVS-infected animals. However, for animals infected with SchuS4, only ciprofloxacin was efficacious and prolongation of treatment rescued all animals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850512      PMCID: PMC3457351          DOI: 10.1128/AAC.01104-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Cat-bite tularemia in a seventeen-year-old girl treated with ciprofloxacin.

Authors:  R Arav-Boger
Journal:  Pediatr Infect Dis J       Date:  2000-06       Impact factor: 2.129

2.  Treatment of tularemia with levofloxacin.

Authors:  E A Aranda
Journal:  Clin Microbiol Infect       Date:  2001-03       Impact factor: 8.067

3.  Treatment of tularemia with ciprofloxacin.

Authors:  O Scheel; R Reiersen; T Hoel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

4.  Antibiotic prophylaxis and therapy of airborne tularemia.

Authors:  W D Sawyer; H G Dangerfield; A L Hogge; D Crozier
Journal:  Bacteriol Rev       Date:  1966-09

Review 5.  Treatment of tularemia with fluoroquinolones: two cases and review.

Authors:  A P Limaye; C J Hooper
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

Review 6.  Tularemia as a biological weapon: medical and public health management.

Authors:  D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis.

Authors:  Gal Markel; Erez Bar-Haim; Eran Zahavy; Hila Cohen; Ofer Cohen; Avigdor Shafferman; Baruch Velan
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

Review 8.  Streptomycin and alternative agents for the treatment of tularemia: review of the literature.

Authors:  G Enderlin; L Morales; R F Jacobs; J T Cross
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

Review 9.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection.

Authors:  Erez Bar-Haim; Orit Gat; Gal Markel; Hila Cohen; Avigdor Shafferman; Baruch Velan
Journal:  PLoS Pathog       Date:  2008-11-21       Impact factor: 6.823

View more
  6 in total

1.  A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.

Authors:  Charlotte A Hall; Helen C Flick-Smith; Sarah V Harding; Helen S Atkins; Richard W Titball
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

2.  Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.

Authors:  Shahar Rotem; Ofer Cohen; Erez Bar-Haim; Liat Bar-On; Sharon Ehrlich; Avigdor Shafferman
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

Review 3.  Francisella tularensis Susceptibility to Antibiotics: A Comprehensive Review of the Data Obtained In vitro and in Animal Models.

Authors:  Yvan Caspar; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2017-04-11       Impact factor: 5.293

4.  Bis-indolic compounds as potential new therapeutic alternatives for tularaemia.

Authors:  Yvan Caspar; Vivien Sutera; Sandrine Boisset; Jean-Noël Denis; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-02-27       Impact factor: 5.293

5.  Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment.

Authors:  Adva Mechaly; Uri Elia; Ron Alcalay; Hila Cohen; Eyal Epstein; Ofer Cohen; Ohad Mazor
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

Review 6.  Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.

Authors:  Manfred S Green; James LeDuc; Daniel Cohen; David R Franz
Journal:  Lancet Infect Dis       Date:  2018-10-16       Impact factor: 25.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.